Biotron Limited, which develops innovative treatments for viral diseases that have unmet medical needs, recently released information about its leading drug, a combined treatment for HIV-1 and Hepatitis C virus (HCV).
BIT225 shows early proof-of-concept data from its clinical trials with activity in HIV-1 as well as HCV. As a pan-genotypic drug, it provides notable potential in being included in a novel category of oral direct-acting antiviral drugs to treat HCV.
The drug is being considered as a filler for treatment gaps that have continued in the field, especially concerning HCV genotype 3.
BIT225 also is being developed as a treatment option for HIV-1. It is a first-in-class drug that can target the virus even as it hides in microphage reservoir cells. Until now, HIV has been able to escape drug therapies by hiding in these reservoirs. The virus uses these cell reservoirs to produce an ongoing supply of the virus to continue settling in the host’s body.
BIT225 shows evidence that it is effective in treating these reservoir cells.
